Abstract | SCOPE: METHODS AND RESULTS: A polysaccharide named Fuc-S, with a molecular weight of 156 kDa, was prepared by the ultrasonic degradation of fucoidan. Monosaccharide composition, FTIR, methylation, and NMR spectral analysis indicated that Fuc-S may have a backbone consisting of →3)-α-L-Fucp-(1→, →4)-α-L-Fucp-(1→ and →3, 4)-α-D-Glcp-(1→. Moreover, male C57BL/6 mice were fed three cycles of 1.8% dextran sulfate sodium (DSS) for 5 days and then water for 7 days to induce colitis. The longitudinal microbiome alterations were evaluated using 16S amplicon sequencing. In vivo assays showed that Fuc-S significantly improved clinical manifestations, colon shortening, colon injury, and colonic inflammatory cell infiltration associated with DSS-induced chronic colitis in mice. Further studies revealed that these beneficial effects were associated with the inhibition of Akt, p-38, ERK, and JNK phosphorylation in the colon tissues, regulating the structure and abundance of the gut microbiota, and modulating the host-microbe tryptophan metabolism of the mice with chronic colitis. CONCLUSION: Our data confirmed the presence of glucose in the backbone of fucoidan and provided useful information that Fuc-S can be applied as an effective functional food and pharmaceutical candidate for IBD treatment.
|
Authors | Haitao Xiao, Jinxiu Feng, Jiao Peng, Peigen Wu, Yaoyao Chang, Xianqian Li, Jinhui Wu, Haifeng Huang, Huan Deng, Miao Qiu, Yuedong Yang, Bin Du |
Journal | Marine drugs
(Mar Drugs)
Vol. 21
Issue 1
(Dec 25 2022)
ISSN: 1660-3397 [Electronic] Switzerland |
PMID | 36662189
(Publication Type: Journal Article)
|
Chemical References |
- Dextran Sulfate
- Sulfates
- Tryptophan
- Oligosaccharides
|
Topics |
- Animals
- Male
- Mice
- Colitis
(chemically induced, drug therapy, metabolism)
- Colon
(metabolism)
- Dextran Sulfate
- Disease Models, Animal
- Gastrointestinal Microbiome
- Mice, Inbred C57BL
- Sulfates
(pharmacology)
- Tryptophan
(pharmacology)
- Ultrasonics
- Oligosaccharides
|